



HUMANITARIAN AID
PROGRAM

IMPACT REPORT 2024

The WFH Humanitarian Aid Program: **A BEACON OF HOPE FOR PEOPLE WITH INHERITED BLEEDING DISORDERS**

Hello friends,

2024 was another productive year for the WFH Humanitarian Aid Program. We once again delivered life-changing support to countries around the world.

We also celebrated a major milestone: the 10-year anniversary of Sanofi and Sobi answering the WFH call to action, which urged manufacturers to support the global inherited bleeding disorders community through the donation of treatment products and financial aid to the WFH Humanitarian Aid Program.

Thanks to all our sponsors, the WFH Humanitarian Aid Program continues to support countries by providing them with predictable treatment product donations, education, training, and government lobbying assistance. The objective? Help countries along their journey to sustainability in inherited bleeding disorders care. While there is still a long way to go in this ambitious goal, we accomplished much last year.

3,801 patients
on prophylactic treatment


291 million IUs
of factor distributed

2.8 million mg
of non-factor replacement
therapy distributed

17,533 people
with inherited bleeding
disorders (PWBDs) treated

**37,907 acute bleeding
episodes** managed

2,958 surgeries performed



2024 objectives

I am also happy to report that we met all of our set objectives for 2024.

- ✓ **Accomplished:** Increase by 5% the number of children on prophylaxis—**8% achieved**
- ✓ **Accomplished:** Increase by 10% the number of PWBDs treated—**12% achieved**
- ✓ **Accomplished:** Train specialists from seven countries on ultrasound diagnosis and synovectomy
- ✓ **Accomplished:** Work towards securing donations of bypassing agents for treating acute bleeds in PWBDs with inhibitors

2025 objectives

Next year, our objectives are even more ambitious:

- **Increase by 20%** the number of children on prophylaxis
- **Increase by 10%** the number of PWBDs treated
- **Train specialists from seven countries** on ultrasound diagnosis and synovectomy
- **Secure donations** of bypassing agents for treating acute bleeds in PWBDs with inhibitors

WFH Humanitarian Aid Program support **since 1996**

In addition to the above objectives, we continue to work to meet other requirements in the community which are just as important. For example, there continues to be a need for donations of factor IX product, as well as bypassing agents. There is also a strong need for donations of new classes of products that will help bring care to the next level for the people we support around the world. We are confident that in 2025—and beyond—our generous sponsors will recognize and support these needs in the name of Treatment for All.

Our successes in 2024 were made possible by the dedication of our volunteers, staff and the commitment of our partners: WFH national member organizations (NMOs), hemophilia treatment centres (HTCs), healthcare professionals (HCPs), governments, donors, members of the WFH and WFH USA boards, and our global inherited bleeding disorders community.

On behalf of the WFH I would like to thank all our partners for their continued support.



Assad E. Haffar, MD, MSc

WFH Medical, Humanitarian Aid
& Medical Training Director

6,500+

patients on prophylactic treatment

2.2+ billion IUs

of factor distributed since inception
of Program in 1996

12+ million mg

of non-factor replacement therapy

29,000+

people with inherited bleeding disorders
(PWBDs) treated

410,000+

acute bleeding episodes managed

12,000+

surgeries facilitated

CASE STUDY

Morocco

FACTOR DONATED IN 2024
2.7 million IUs

PATIENTS TREATED IN 2024
485

Challenges and hope for PWBDs in Morocco

The WFH has been working in partnership with the ministry of health (MOH) and the NMO in Morocco for many years. One of the most encouraging outcomes of these efforts has been improving the quality of life of PWBDs in the country. Patient visits by the Program team at an HTC and at a home showed how Program support has helped give people—and especially children—with bleeding disorders hope for a better future.



Click here to read
the full story
or scan the QR code



Increasing care and changing lives in Senegal

In 2024, the WFH Humanitarian Aid Program team went to Senegal to visit a hemophilia treatment centre, the ministry of health, a blood bank, and PWBDs who have benefitted from WFH support, to see how care levels are progressing, and to determine how to best optimize support in the future. The drastic changes that have been brought to the country thanks to the Program underscored the importance of continuous support and dependable treatment product donations for PWBDs in emerging economies.



 [Click here to read the full story](#)
or scan the QR code

CASE STUDY

Senegal

FACTOR DONATED IN 2024
1.49 million IUs

NON-FACTOR REPLACEMENT THERAPY DONATED IN 2024
56,700 mgs

PATIENTS TREATED IN 2024
180

IMPACT IN ACTION

The WFH Humanitarian Aid Program works to improve the lives of people with inherited bleeding disorders (PWBDs), giving them a quality of life that previous generations would not have thought possible.

The Program operates based on three key action pillars: supporting outreach and identification, improving quality of life, and enabling sustainable care. These pillars drive our main support activities: delivering donated factor and non-factor replacement therapy, conducting training events and providing logistics support.

1

Supporting outreach and identification by...

- Training general HCPs on how to recognize inherited bleeding disorders
 - Supporting initiatives with local organizations to find new patients
 - Encouraging our partners to increase laboratory diagnosis by providing both educational and logistics support
 - Providing reagents for selected laboratory tests
-

2

Improving quality of life by...

- Collaborating with physicians to provide critical factor and non-factor replacement therapy donations
 - Making life-changing surgery possible through sustainable and predictable treatment donations
 - Facilitating access to care for new and existing PWBDs by working with WFH NMOs and HTC
 - Encouraging the collection of patient outcome data to document improvements in care
-

3

Enabling sustainable care by...

- Supporting the establishment of medical facilities so that NMOs and HTCs can provide patients with lasting care
- Demonstrating to governments the value of treating PWBDs to support advocacy initiatives using either factor or non-factor replacement therapy
- Informing and training HCPs on new classes of treatment and new treatment methods in line with the WFH Guidelines for the Management of Hemophilia, 3rd edition



**DELIVERING
CARE**



**MAKING SUSTAINABLE
CARE POSSIBLE**




**ADVOCATING
FOR CARE**

DELIVERING CARE

Since the inception of the program in 1996, a total of **2.2+ billion** of factor and **12.2+ million mg of non-factor replacement therapy** have been donated worldwide.

Key Performance Indicators (KPIs)

Acute bleeds treated versus people with hemophilia (PWH) on prophylaxis since 2020




Because more patients are on prophylaxis, the number of acute bleeds dropped significantly in 2024 as it did in 2023.

Note: The WFH Quality Management System (QMS) and Standard Operating Procedures (SOPs) ensure that the WFH Humanitarian Aid Program respects all good distribution practices (GDP) requirements.

29,000+

Hemophilia A and B patients treated (cumulative) since 2020




3,351

People with hemophilia (PWH) on prophylaxis under 10 years of age (cumulative) since 2020



2,958

Surgeries since 2020





CASE STUDY

Benin

FACTOR DONATED IN 2024
600,000 IUs

NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2024
22,700 mgs

PATIENTS TREATED IN 2024
29

Changing lives through prophylaxis in Benin

Thanks to WFH Humanitarian Aid Program, the level of care in Benin has increased significantly since 2015. Higher amounts of donated factor have allowed the NMO to begin offering prophylactic treatment to its members—something which would have been unthinkable only a few years ago. In the past, patients faced frequent acute bleeds, sometimes every three months or even monthly. Now that the supply of factor is stable, PWBDs can go up to eight months without an acute bleed.



 [Click here to read the full story or scan the QR code](#)

LEVERAGING TRAINING AND LOGISTICS TO MAKE SUSTAINABLE CARE POSSIBLE

Training, logistics and compliance support are key endeavours for the WFH Humanitarian Aid Program. These activities provide the education and guidance that countries need to develop their infrastructure to provide lasting support.

Training strategies

Supporting communities

The expansion of the WFH Humanitarian Aid Program has drastically changed how PWBDs are supported. In the past, care was focused almost exclusively on acute bleeds—often for emergency situations. Now, care has moved in a much more sustainable direction, and the Program has adapted its training accordingly. This has been made possible by the following:

- Significantly higher volumes of treatment product donations
- More consistent and dependable shipping of treatment product
- Longer shelf life for treatment products
- Option to request special potencies of treatment product

As a result of this positive evolution, training has increasingly shifted from emergency care to procedures that aim to improve the long-term quality of life of PWBDs, such as:

- Prophylaxis, especially for children under five years of age
- Corrective surgeries
- Joint care
- Eradication of inhibitors with immune tolerance induction (ITI)

Training KPIs

KPIs	2020	2021	2022	2023	2024	2023 to 2024 % increase
Number of attendees	691	1,468	470	374	435	16.3%
Virtual	691	1,468	364	284	285	0.4%
In-person	0	0	106	90	150	66.7%

Evaluating that support

The Knowledge Attitude Practice (KAP) model helps the WFH Humanitarian Aid Program team evaluate the lasting impact of training. The model looks at the sharing of Knowledge, the Attitude of participants after training has been completed, and the change in Practice of applying the knowledge learned.

100%


of workshop attendees will make improvements to their practice

94%

of attendees are more confident in their understanding of how to develop, initiate and maintain prophylaxis for PWBDs

75%

of the survey respondents will be applying the concept of low-dose prophylaxis for eligible PWBDs



CASE STUDY

Nepal

FACTOR DONATED IN 2024
5.2 million IUs

**NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2024**
230,600 mgs

PATIENTS TREATED IN 2024
412

Supporting NMO advocacy in Nepal

The WFH Humanitarian Aid Program has empowered the Nepal Hemophilia Society (NHS) to secure legal recognition of hemophilia as a disability, advocate for free treatment, and improve care for PWBDs. Through collaborations and government support, the NHS has achieved milestones like a 10-year strategic plan, better access to treatment, and enhanced care facilities, significantly improving the lives of PWBDs.



[Click here to read the full story or scan the QR code](#)

Logistics support

Getting donated factor and non-factor replacement therapy to where it needs to be quickly and efficiently is a key responsibility for the WFH Humanitarian Aid Program team. In 2024, we continued to develop creative solutions to limit the risk of potentially catastrophic interruptions in treatment product donations to key areas.

KPIs	2021	2022	2023	2024
Shipments	318	269	347	276
Vials	633,453	422,400	773,131	535,582
Gross weight (tons)	113	82	139	160
Compliance assessments	20	21	23	22

ADVOCATING FOR CARE

Case Studies

Along with other WFH global and local advocacy efforts, the WFH Humanitarian Aid Program works with NMOs to advocate with governments to recognize and support their inherited bleeding disorders communities. Ultimately, government buy-in is required for a country to be able to provide fully sustainable care. Here are two video series which demonstrate the work the WFH Humanitarian Aid Program is doing in Cambodia and in India.



Cambodia video series

**FACTOR DONATED
IN 2024**

4 million IUs

**NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2024**

142,000 mgs

**PATIENTS TREATED
IN 2024**

162

In 2024, the WFH Humanitarian Aid Program team went to Cambodia to see firsthand what progress was being made, and to see where future efforts should be focused. They saw very quickly that care has improved significantly since the WFH first started working in the country 15 years ago. The Program provides donated treatment products to Cambodia and supports the effective use these donations through training with different stakeholders. This tailored support has been key to optimizing care in the country.



[Click here to watch
the videos](#)
or scan the QR code

India video series

**FACTOR DONATED
IN 2024**

67.7 million IUs

**PATIENTS TREATED
IN 2024**

5,357

During a recent visit to India, the WFH Humanitarian Aid Program team saw the result of years of WFH-led collaboration between healthcare professionals, organizations, sponsors, and the government in the country. Long-term collaboration with the Hemophilia Federation India (HFI) has also been fruitful, helping the NMO grow from three to 99 chapters over the last four decades.




[Click here to watch
the videos](#)
or scan the QR code




Countries that collaborated with the WFH in 2024

75 countries received donations

Afghanistan	El Salvador	Laos	Mongolia	Niger	Sudan
Angola	Eritrea	Lebanon	Morocco	Nigeria	Suriname
Armenia	Ethiopia	Madagascar	Mozambique	Pakistan	Syria
Bahamas	Gabon	Malawi	Myanmar	Paraguay	Tajikistan
Bangladesh	Ghana	Maldives	Nauru	Peru	Tanzania
Barbados	Guinea	Mali	Nepal	Philippines	Togo
Belize	Guyana	Mauritania	Nicaragua	Rwanda	Trinidad and Tobago
Benin	Honduras			Saint Lucia	Uganda
Bolivia	India			Senegal	Uzbekistan
Botswana	Indonesia			Sierra Leone	Venezuela
Burkina Faso	Ireland			South Africa	Yemen
Burundi	Jamaica			Sri Lanka	Zambia
Cambodia	Jordan				Zimbabwe
Cameroon	Kenya				
Congo	Kosovo				
Côte d'Ivoire	Kyrgyzstan				
Democratic Republic of the Congo (DRC)					
Djibouti					
Dominican Republic					
Egypt					



Note: most countries that received factor also received training.



WORKING TOGETHER TO SUPPORT TREATMENT FOR ALL

Founding Visionary Contributors



"Sanofi has always believed in the responsibility to support patients with limited or no access to treatment and care. Through its philanthropic organization Foundation S and together with Sobi, we are honoured to be a long-term partner to a program that has helped ensure more equitable access to treatments and elevated the standard of care for people living with hemophilia in the developing world. We are proud to collaborate in addressing this global health challenge."

—Audrey Duval, EVP, Corporate Affairs,
Sanofi

"Sobi is honoured to contribute to a program that provides predictable and sustainable care, and continues to make such a profound difference in the lives of those affected by hemophilia. Our collaboration with Sanofi and the WFH has allowed us to witness first-hand the transformative impact the WFH Humanitarian Aid Program has on people, families, and communities around the world. It is a privilege to support this vital program as Founding Visionary Contributors."

—Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer, **Sobi**

Visionary Contributors



"At Bayer, we are guided by our vision of 'Health for All, Hunger for None'. This is why we are very proud to work in close collaboration with the WFH Humanitarian Aid Program to provide support and access to treatment for people with hemophilia where it is needed most. As part of our long-standing commitment to the global hemophilia community, the strong alliance between the WFH and Bayer is both a testament and a great opportunity to make a life changing difference in people's lives."

—Martin Renze-Westendorf, Global Therapeutic Area Head for Hemophilia, **Bayer**



"CSL Behring is committed to delivering on 'Our Promise' to improve the lives of people living with rare and serious diseases. Patients' access to life-saving medicines is a global challenge that shouldn't be ignored, and we are proud of our longtime partnership with the WFH. We share a commitment to enabling access to care for people with bleeding disorders around the world. As a Visionary Contributor, CSL Behring is proud to be at the forefront of providing treatments for the hemophilia community and helping improve quality of life."

—Paul McKenzie, CEO and Managing Director, **CSL**



"At Roche, we are guided by our vision to 'do now what patients need next'. We are proud to support the WFH Humanitarian Aid Program in its mission to help address the need for greater access to therapies, particularly in developing countries. Effective therapies can contribute to improving the quality of life of people with hemophilia A and their families. Listening to, and collaborating with, the hemophilia community in their efforts to improve the lives of people living with hemophilia A is a top priority for Roche. Improving the healthcare systems and working towards greater government engagement in all countries is important for creating sustainable access to therapies."

—Daud Chaudry, Global Head of Hemophilia, **Roche**

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support to people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care.

None of this would be possible without the generous support of our sponsors.

Leadership Contributor

GRIFOLS

"The moral measure of a society is not how it treats those who already have their basic human needs met, but rather, how it treats those who do not. By this standard, the WFH Humanitarian Aid Program is excelling beyond measure. It is an honour for Grifols to support the success of the program with regular and ongoing donations of clotting factor products destined for parts of the world where access to treatment is not guaranteed."

—Christopher Healey, Senior Vice President, Corporate Affairs, **Grifols**

Contributor



"Takeda deeply appreciates the important work of the WFH to close the treatment gap and educate on the critical unmet need for therapies in many countries around the world. Takeda is proud to support the Humanitarian Aid Program with its goal to achieve health equity for persons with bleeding disorders worldwide."

—Giles Platford, President, Plasma-Derived Therapies Business Unit, **Takeda**

Other Partners



"Working together with the WFH, we have built a lasting partnership to deliver aid to the people who need it most globally. DSV's team of experts is committed to excellence at every step. Every project and shipment is handled with the care and attention it deserves. We are proud to help WFH make a difference with its life saving efforts globally to keep supply chains flowing worldwide."

—Kevin Carlson, General Manager – National Sales, **DSV**



"Pontem Innovations is a proud data partner to the WFH. Over the years, we have witnessed the commitment of the WFH to the modernization of their data tools, to workflow efficiency, and to continuous improvement. Their impact on the global community is immense, and Pontem is honoured to be part of their journey to change the lives of people with bleeding disorders."

—Jessa Kuchmak, Co-Founder and Co-CEO, **Pontem Innovations**



"Hemophilia of Georgia was started by families with the mission to support each other and create a future for all people impacted by bleeding disorders. More than 50 years later, we continue to honour this commitment by partnering with the World Federation of Hemophilia to bring hope, lessen the effects of bleeding disorders, and develop sustainable programs in low and middle-income countries. We know that by working hand-in-hand with our partners across the world, we can save lives, improve outcomes, and create a world where people with bleeding disorders thrive."

—Deniece Chevannes, Vice President of Public Policy, Health Equity, and Research, **Hemophilia of Georgia**

WFH Humanitarian Aid Program

KEY PERFORMANCE INDICATORS

KPIs	2020	2021	2022	2023	2024
Operational metrics					
Patients treated by donations (cumulative)	20,048	22,159	25,183	26,143	29,632
Total donations in MIUs	146	307	197	265	291
Total donations in mgs of non-factor replacement therapy	809,220	2,561,750	3,264,800	2,783,250	2,800,000
Number of countries receiving donations	69	74	72	78	76
Mean age of PWH* receiving treatment	22	21	21	20	22
Total number of infusions related to acute bleed treatment	68,889	159,458	63,492	116,067	141,494
Impact metrics					
Number of countries doing surgeries	25	26	22	32	31
New countries doing surgeries	0	2	2	8	3
Total number of surgeries†	856	838	1,461	1,768	2,958
Life and limb-saving surgeries†	121	83	72	83	167
Number of acute bleeds treated	51,401	62,349	41,771	30,598	37,907
Impact metrics (cumulative)					
Number of PWH on prophylaxis	1,804	2,836	3,964	6,429	6,591
PWH on prophylaxis under 10 years of age	1,145	1,251	1,540	3,102	3,351
Activity metrics					
Number of workshop attendees	691	1,468	470	385	435
Virtual	691	1,468	364	284	285
In-person	-	-	106	101	150

* PWH: person with hemophilia

† Surgeries increased dramatically thanks to the donation of high potency treatment products.



A DECADE OF IMPACT:
**SANOFI AND SOBI
ANSWER THE WFH
CALL TO ACTION**

10
YRS

2014 TO 2024

Ten years after answering the WFH call to action to support the global inherited bleeding disorders community through the donation of treatment products and financial aid.



The WFH call to action

In countries with little or no access to care for people with bleeding disorders (PWBDs), treatment often goes no further than managing acute bleeds in the emergency room. The way to bring the level of care to the next level—where quality of life can be improved—is to ensure that a dependable supply of treatment product is available so that PWBDs can be put on prophylactic treatment. That's why in 2012, Mark W. Skinner, the President of the WFH at the time, issued a call to action urging manufacturers to support the global inherited bleeding disorders community through the donation of treatment products and financial aid to the WFH Humanitarian Aid Program.

Sanofi and Sobi make history

In 2014, this call to action was answered by Sanofi and Sobi, and support for the global bleeding disorders community increased significantly. Now—ten years after the first major donation—the totals are staggering.

Treatment product donations

The unprecedented factor and non-factor treatment product donations have improved care for thousands, improving—and often, saving—lives.

2 BILLION IUs of factor replacement therapy donated in 10 years

10 MILLION mgs of non-factor replacement therapy donated in 10 years

600 MILLION IUs of treatment products donated in the first 5 years alone

30,000 PATIENTS supported

400,000 BLEEDS treated


10,000 SURGERIES facilitated

3,000 CHILDREN provided with access to prophylactic treatment

Funding support

In addition to treatment products, Sanofi and Sobi have also contributed funding which has allowed the Program to provide training for healthcare professionals (HCPs) on the effective and safe use of treatment products. The funding also allowed the WFH to launch education initiatives to ensure that individuals with bleeding disorders can best care for themselves.

Funding also made it possible for the Program to bolster the effectiveness of national member organizations (NMOs). Now, these organizations can use WFH data from their communities to demonstrate to governments the significant impact of consistent access to treatment—allowing them



to enhance their advocacy efforts. The Program has also facilitated closer collaboration between hemophilia treatment centres (HTCs) and NMOs, improving the alignment between the needs of PWBDs and the services offered by the healthcare system.

Dear friends,

The unwavering support of Sanofi and Sobi—uniquely recognized as our Founding Partners—has saved and transformed countless lives. They were the first companies to answer the WFH call to action, and their leadership inspired others to follow them and provide their own contributions. Today, we are proud to count seven companies as supporters of the WFH Humanitarian Aid Program.

Thanks to the generosity of the companies that champion our efforts, people with bleeding disorders (PWBDs) who once faced dire outcomes now have access to life-changing treatments and the chance to lead fulfilling lives. Their donations bring hope to communities that previously had none, empowering families and strengthening healthcare systems. From children who can now play with their peers, to adults who can support their families, the impact of these donations is profound and lasting. Hemophilia used to mean a death sentence. That is no longer the case.

I thank Sanofi and Sobi on behalf of the World Federation of Hemophilia. I thank them for their support, compassion, and partnership. Together, we are building a future where no one is left behind.



Assad E. Haffar, MD

WFH Medical, Humanitarian Aid & Medical Training Director

Dear friends,

The expanded WFH Humanitarian Aid Program has profoundly impacted the lives of people with hemophilia worldwide. This is thanks to the invaluable support provided by Sanofi and Sobi.

Their partnership has enabled the introduction of prophylaxis, life-changing orthopedic surgeries, and home-based treatment, transforming lives and empowering families to manage their health with dignity and hope. These achievements are key steps toward the WFH vision of “Treatment for All.” Their contributions are more than support—they are a lifeline that brings hope and a brighter future to those who need it most.

On behalf of the World Federation of Hemophilia and the communities we serve, thank you, Sanofi and Sobi, for your dedication to this mission. Together, we are creating lasting change.



Mark W. Skinner

Board Member, WFH USA

“Sanofi has a longstanding commitment to addressing barriers to treatment and helping people around the world access sustainable care. For the past ten years, together, with Sobi, we have been a founding visionary contributor to the WFH Humanitarian Aid Program, helping to address the significant treatment gap that exists for people living with hemophilia in developing countries. Not only does this program provide those most in need with a predictable and sustainable supply of therapy, it also supports earlier diagnosis, education, training and advocacy. We look forward to continuing our commitment to the hemophilia community through our collaboration with the World Federation of Hemophilia.”

—Alaa Hamed, Global Head, Medical Affairs Rare Disease, **Sanofi**


“As we look back on the past decade of Sobi’s collaboration as Founding Visionary Contributors supporting the WFH Humanitarian Aid Program, we take immense pride in the enduring impact of our united efforts and the difference this program continues to make in the lives of people with hemophilia around the globe. As a manufacturer, we recognize our responsibility to continue to support and advance the crucial work of the WFH over the long-term. Sobi remains committed to the hemophilia community as we work to improve access to sustainable and predictable treatment worldwide.”

—Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer, **Sobi**


From 2013 until 2024

10
YRS


Millions of IUs donated



Cumulative number of patients treated



Number of countries receiving factor



A celebration of the past—

AND A FOCUS ON THE FUTURE

By providing a predictable supply of donations to countries around the world, Sanofi and Sobi have made it possible for the WFH Humanitarian Aid Program to truly enhance the quality of life of PWBDs. Many of these people are children who can now look forward to a longer, and less pain-filled life than previous generations. Instead of death, there is now hope. Instead of parents sacrificing everything for their children, parents can now work and provide their families with more than just the basic necessities of life.

On behalf of the global inherited bleeding disorders community, the WFH thanks Sanofi and Sobi for answering the call to action. Thank you for the first historic donation—and for each donation that has followed over the last decade. Your support has been saving lives for a decade. We know it will continue to do so for another decade—and beyond.





CASE STUDY

Jamaica

FACTOR DONATED IN 2024
614,800 IUs

NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2024
99,700 mgs

PATIENTS TREATED IN 2024
65

Changing lives in Jamaica

The WFH Humanitarian Aid Program has transformed care for Jamaica's bleeding disorders community. Once plagued by limited treatment options, PWBDs now have access to prophylaxis, reducing bleeds and improving their quality of life. During a visit, Program team members heard stories of lives saved, like a newborn rescued from a critical bleed, and families empowered by the benefits of non-factor replacement therapy.



Click here to read
the full story
or scan the QR code



YOUR CONTINUED SUPPORT HELPS US

Increase quality of care

Increase the number of patients treated

Improve quality of life

Enhance diagnosis

Advocate for better care

For more information, please contact us at:

WORLD FEDERATION OF HEMOPHILIA

1184 rue Sainte-Catherine Ouest
Bureau 500, Montréal (Québec)
H3B 1K1 Canada
T +1 514.875.7944

humanitarianaid@wfh.org
wfh.org
treatmentforall.org



Charitable solicitations for the common purposes of WFH and WFH USA within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.

Printed in Canada – Design: Lanla.com

Cover photo: WFH - India visit - November 2024